Critical Care

, 23:322 | Cite as

Correction to: Procalcitonin levels in candidemia versus bacteremia: a systematic review

  • Andrea CortegianiEmail author
  • Giovanni Misseri
  • Mariachiara Ippolito
  • Matteo Bassetti
  • Antonino Giarratano
  • Ignacio Martin-Loeches
  • Sharon Einav
Open Access




Correction to: Crit Care (2019)23:190

The author wish to note there are three imprecisions in the article [1]. Part of the sentence “All the studies identified were retrospective, except for three prospective and one secondary analysis of a prospectively collected dataset” was omitted, leading to the declaration that “…the studies identified were all retrospective, except for one secondary analysis of a prospective dataset” in the “Results” of the abstract and “All studies were retrospective, except for one secondary analysis of a prospectively collected dataset” under the subheading “Characteristics of the included studies”. Table 1 reports the correct number of prospective analyses. Also, the number of excluded records in Fig. 1 should be 1132 and not 1136. Finally, the procalcitonin (PCT) value in the Gram + group in the paper by Basetti et al. [2] should be 8.9 ± 7.5 in Table 1. This has now been included in this correction article.




Authors’ contributions

AC, MI, SE, checked the data and draft the manuscript. All authors read and approved the final correction statement.



Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

IML: Lectures: Thermofisher, Polyphor, J&J, Virogates, MSD; Advisory board: Fresenius Kabi, MaaT Pharma, Bayer, Gilead, Clinigen, Biotest, Accelerate (all unrelated to the present work). AG: received fees for consultancies or lectures from Orion, Pfizer, MSD (all unrelated to the present work). MB: has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, AstraZeneca, Bayer, Biomerieux, Cidara, Cubist, Gilead, Pfizer, Melinta Therapeutics, Menarini, MSD, Nabriva, Paratek, Roche, Shionogi, Tetraphase, The Medicines Company and Astellas Pharma Inc. (all unrelated to the present work). All other authors declare no relevant competing interests.


  1. 1.
    Cortegiani A, Misseri G, Ippolito M, Bassetti M, Giarratano A, Martin-Loeches I, et al. Procalcitonin levels in candidemia versus bacteremia: a systematic review. Crit Care. 2019;23:190. Scholar
  2. 2.
    Bassetti M, Russo A, Righi E, Dolso E, Merelli M, Cannarsa N, et al. Comparison between procalcitonin and C-reactive protein to predict blood culture results in ICU patients. Crit Care. 2018;22:252. Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.). Section of Anesthesia, Analgesia, Intensive Care and EmergencyPoliclinico Paolo Giaccone. University of PalermoPalermoItaly
  2. 2.Infectious Diseases Division, Department of MedicineUniversity of Udine and Santa Maria della Misericordia University Hospital. Piazzale Santa Maria della Misericordia 15UdineItaly
  3. 3.Multidisciplinary Intensive Care Research Organization (MICRO), St. James’s HospitalDublinIreland
  4. 4.Hospital ClinicUniversidad de Barcelona, CIBEResBarcelonaSpain
  5. 5.Intensive Care Unit of the Shaare Zedek Medical Medical Centre and HebrewUniversity Faculty of MedicineJerusalemIsrael

Personalised recommendations